Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
暂无分享,去创建一个
J G Coen van Hasselt | Jia-Jye Lee | Evren U Azeloglu | W. Janssen | E. Azeloglu | G. Jayaraman | Hong Li | Chengguo Wei | E. Jaimes | F. Salem | B. Murphy | C. Cuttitta | Hong Li | Rhodora C Calizo | Smiti Bhattacharya | Chengguo Wei | Jenny S Wong | Robert J Wiener | Xuhua Ge | Nicholas J Wong | Christina M Cuttitta | Gomathi Jayaraman | Vivienne H Au | William Janssen | Tong Liu | Fadi Salem | Edgar A Jaimes | Barbara Murphy | Kirk N Campbell | J. V. van Hasselt | J. V. Hasselt | R. C. Calizo | N. J. Wong | Tong Liu | S. Bhattacharya | K. Campbell | Jia-Jye Lee | Xuhua Ge | Jenny S. Wong | R. Wiener | Vivienne H. Au | Gomathi Jayaraman | Nicholas J. Wong | Smiti Bhattacharya
[1] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[2] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[3] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[4] R. Kurzrock,et al. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] S. Orrenius,et al. The cytoskeleton as a target in quinone toxicity. , 1990, Free radical research communications.
[6] S. Shankland,et al. Podocytes in culture: past, present, and future. , 2007, Kidney international.
[7] Jian-Kang Chen,et al. EGF receptor deletion in podocytes attenuates diabetic nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.
[8] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[9] Harlan M. Krumholz,et al. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 , 2017, JAMA.
[10] S. Shankland,et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. , 2005, Journal of the American Society of Nephrology : JASN.
[11] B. Aronow,et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data , 2016, Nature Biotechnology.
[12] A. Michie,et al. Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12 , 2012, PloS one.
[13] R. Iyengar,et al. Cell shape information is transduced through tension-independent mechanisms , 2017, Nature Communications.
[14] J. Verweij,et al. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.
[15] D. Singer,et al. Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS) , 2019, CNS Drugs.
[16] W. Kriz,et al. Induction of differentiation in cultured rat and human podocytes. , 1997, Journal of the American Society of Nephrology : JASN.
[17] J. He,et al. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics , 2017, The Journal of Biological Chemistry.
[18] Anne E Carpenter,et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.
[19] Pablo A Iglesias,et al. Molecular Mechanisms of Cellular Mechanosensing , 2013, Nature materials.
[20] G. Remuzzi,et al. Podocyte–actin dynamics in health and disease , 2016, Nature Reviews Nephrology.
[21] P. Caroni,et al. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase , 1998, Nature.
[22] A. Gharavi,et al. Novel mutations in the inverted formin 2 gene of Chinese families contribute to focal segmental glomerulosclerosis. , 2015, Kidney international.
[23] N. Visa,et al. Actin in transcription and transcription regulation. , 2006, Current opinion in cell biology.
[24] R. Kurzrock,et al. Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. , 2012 .
[25] E. Petricoin,et al. The spectra count label-free quantitation in cancer proteomics. , 2012, Cancer genomics & proteomics.
[26] Ravi Iyengar,et al. Fragility of foot process morphology in kidney podocytes arises from chaotic spatial propagation of cytoskeletal instability , 2017, PLoS Comput. Biol..
[27] M. Chonchol,et al. Association of complete recovery from acute kidney injury with incident CKD stage 3 and all-cause mortality. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] Ravi Iyengar,et al. Interconnected Network Motifs Control Podocyte Morphology and Kidney Function , 2014, Science Signaling.
[29] S. Shankland,et al. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. , 2006, Kidney international.
[30] B. Fu,et al. Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis , 2020, Annals of translational medicine.
[31] Avi Ma'ayan,et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.
[32] Kevin D Costa,et al. Atomic force microscopy in mechanobiology: measuring microelastic heterogeneity of living cells. , 2011, Methods in molecular biology.
[33] G. Demetri,et al. Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[34] E. Nishida,et al. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization , 1998, Nature.
[35] K. Asanuma,et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. , 2007, Trends in cell biology.
[36] H. Kawachi,et al. p21-activated kinases regulate actin remodeling in glomerular podocytes. , 2010, American journal of physiology. Renal physiology.
[37] Daniel A. Fletcher,et al. Cell mechanics and the cytoskeleton , 2010, Nature.
[38] M. Zeier,et al. Role of podocytes in lupus nephritis. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[39] Kyung Lee,et al. Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes , 2019, Nature Communications.
[40] L. Holzman,et al. Actin-depolymerizing Factor Cofilin-1 Is Necessary in Maintaining Mature Podocyte Architecture* , 2010, The Journal of Biological Chemistry.
[41] D. C. Edwards,et al. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics , 1999, Nature Cell Biology.
[42] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[43] Avi Ma'ayan,et al. Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers , 2012, Bioinform..
[44] Jin-jin Fan,et al. Tacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis , 2015, PloS one.
[45] R. Bruner,et al. The M&A , 2008 .
[46] Kevin D Costa,et al. Cross-bridge cycling gives rise to spatiotemporal heterogeneity of dynamic subcellular mechanics in cardiac myocytes probed with atomic force microscopy. , 2010, American journal of physiology. Heart and circulatory physiology.
[47] A. Ganti,et al. Renal Toxicities of Targeted Therapies , 2015, Targeted Oncology.
[48] F. F. de Melo,et al. Nephrotoxicity in cancer treatment: An overview , 2020, World journal of clinical oncology.
[49] Kyung Lee,et al. Inactivation of integrin-β1 prevents the development of polycystic kidney disease after the loss of polycystin-1. , 2015, Journal of the American Society of Nephrology : JASN.
[50] D. Warnock,et al. Foot Process Effacement Is an Early Marker of Nephropathy in Young Classic Fabry Patients without Albuminuria , 2014, Nephron.
[51] S. Ishibe,et al. The function of endocytosis in podocytes , 2013, Current opinion in nephrology and hypertension.
[52] P. Mitchell,et al. Association of CKD and cancer risk in older people. , 2009, Journal of the American Society of Nephrology : JASN.
[53] H. Wildiers,et al. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[55] M. Saleem,et al. Podocyte RhoGTPases: new therapeutic targets for nephrotic syndrome? , 2019, F1000Research.
[56] Ravi Iyengar,et al. Systems Pharmacology of Adverse Event Mitigation by Drug Combinations , 2013, Science Translational Medicine.
[57] Ferenc Horkay,et al. Determination of elastic moduli of thin layers of soft material using the atomic force microscope. , 2002, Biophysical journal.
[58] Kevin D Costa,et al. Atomic force microscope elastography reveals phenotypic differences in alveolar cell stiffness. , 2008, Journal of applied physiology.
[59] E. Jaimes,et al. Dasatinib-induced nephrotic-range proteinuria. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[60] E. Brown,et al. The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.
[61] J. Stokes,et al. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. , 2009, Leukemia research.
[62] Jeremy S Logue,et al. c-Src activity is differentially required by cancer cell motility modes , 2018, Oncogene.
[63] Richard S. Chadwick,et al. Determination of the elastic moduli of thin samples and adherent cells using conical AFM tips , 2012, Nature nanotechnology.
[64] Liisa Arike,et al. Spectral counting label-free proteomics. , 2014, Methods in molecular biology.
[65] P. Janmey,et al. Similar Biophysical Abnormalities in Glomeruli and Podocytes from Two Distinct Models. , 2018, Journal of the American Society of Nephrology : JASN.
[66] K. Costa,et al. Analysis of indentation: implications for measuring mechanical properties with atomic force microscopy. , 1999, Journal of biomechanical engineering.
[67] Chirag R Parikh,et al. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. , 2012, Kidney international.
[68] J. G. van den Berg,et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. , 2004, Kidney international.
[69] A. Advani,et al. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy , 2011, Nephrology.